We have shown that somatic PTPN11 mutations increase proliferation, activate the Shp2 phosphatase domain, and promote the activation of the PI3K and MAPK pathways in NSCLC cell lines, which is consistent with prior studies in leukaemia [8,9,11,14,29,30]. This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.